immunotherapy

March 25, 2021

Forty-three percent of melanoma patients have chronic complications from immunotherapies

Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.

By Tom Wilemon
December 22, 2020

Arthritis drug may treat immunotherapy-related heart complication

By Tom Wilemon
August 20, 2020

A “torque” for tumor blood vessels

Vanderbilt scientists have discovered a new target for normalizing tumor blood vessels to improve cancer immunotherapies.

By Bill Snyder
June 4, 2020

Potential new cancer target

Vanderbilt researchers have discovered the involvement of a certain type of adenosine receptor in mediating signaling that supports tumor growth and metastasis.

By Bill Snyder
Dona Potter was treated with a new immunotherapy that entails re-engineering a patient’s T cells to target cancer.
February 27, 2020

Patient’s cancer treatment includes new immunotherapy

Dona Potter, 87, rode Harleys and drove 18-wheelers back when men dominated the open highways, and she is still defying expectations.

By Tom Wilemon
January 16, 2020

Journey Home Project supports first CAR-T infusion at VA hospital

The Tennessee Valley Healthcare System performed its first CAR-T infusion recently at the Veterans Administration hospital in Nashville.

By Tom Wilemon
November 7, 2019

Project seeks new way to assess immunotherapy effectiveness

GE Healthcare has awarded researchers in the Vanderbilt University Institute of Imaging Science $2.5 million in funding to develop PET tracer that will determine the effectiveness of immunotherapy in patients early in their treatment course.
By Krystyna Barnard
August 22, 2019

New prostate cancer treatment concept

Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.
By Leigh MacMillan
July 22, 2019

Encephalitis identified as rare toxicity of immunotherapy treatment

Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.
By Tom Wilemon
June 18, 2019

Study identifies critical regulator of tumor-specific T cell differentiation

A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work
By Tom Wilemon
June 6, 2019

Immunotherapy helping 87-year-old man stay on the job

Nine years after being diagnosed with metastatic lung cancer, Roszell Mack Jr., 87, still goes into the office every day thanks to a durable response to the immunotherapy pembrolizumab.
By Tom Wilemon
February 28, 2019

VICC launches new telehealth program for CAR-T patients

Some cancer patients receiving CAR-T infusions can now avoid hospital stays because of a telemedicine program launched by Vanderbilt-Ingram Cancer Center.
By Tom Wilemon
February 21, 2019

Discovery points to new cancer immunotherapy option

An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.
By Leigh MacMillan
1 2 3 4 5